DR. ALEXANDER JEFFREY SHEN, M.D.
Osteopathic Medicine at Lomita Blvd, Torrance, CA
License number
California A77979
Category
Osteopathic Medicine
Type
Hospitalist
License number
California A77979
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
2
3330 Lomita Blvd, Torrance, CA 90505
4404 Lucera Cir, Palos Verdes Estates, CA 90274
4404 Lucera Cir, Palos Verdes Estates, CA 90274
Phone
(310) 891-6623
(310) 891-6673 (Fax)
(310) 373-0659
(310) 891-6673 (Fax)
(310) 373-0659
Professional information
Dr. Alexander J Shen, Torrance CA - MD (Doctor of Medicine)
Address:
TORRANCE MEMORIAL MEDICAL CENTER
3330 Lomita Blvd, Torrance 90505
(310) 325-9110 (Phone)
Torrance Mem Hsptlsts Assocs
3330 Lomita Blvd STE 1, Torrance 90505
(310) 891-6623 (Phone)
3330 Lomita Blvd, Torrance 90505
(310) 325-9110 (Phone)
Torrance Mem Hsptlsts Assocs
3330 Lomita Blvd STE 1, Torrance 90505
(310) 891-6623 (Phone)
Hospitals:
TORRANCE MEMORIAL MEDICAL CENTER
3330 Lomita Blvd, Torrance 90505
Torrance Mem Hsptlsts Assocs
3330 Lomita Blvd STE 1, Torrance 90505
Torrance Memorial Medical Center
3330 Lomita Blvd, Torrance 90505
3330 Lomita Blvd, Torrance 90505
Torrance Mem Hsptlsts Assocs
3330 Lomita Blvd STE 1, Torrance 90505
Torrance Memorial Medical Center
3330 Lomita Blvd, Torrance 90505
Education:
Medical Schools
George Washington University / School of Medicine And Health Sciences
Graduated: 2000
George Washington University / School of Medicine And Health Sciences
Graduated: 2000
Antimicrobial Peptides And Derived Metapeptides
US Patent:
6743769, Jun 1, 2004
Filed:
Mar 13, 2000
Appl. No.:
09/525269
Inventors:
Michael R. Yeaman - Torrance CA
Alexander J. Shen - Torrance CA
Alexander J. Shen - Torrance CA
Assignee:
Harbor-UCLA Research and Education Institute - Torrance CA
International Classification:
A61K 3804
US Classification:
514 2, 514 13, 514 14, 514 17, 530300, 530326, 530327, 530330
Abstract:
The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
Antimicrobial Peptides And Derived Metapeptides
US Patent:
7820619, Oct 26, 2010
Filed:
Aug 25, 2000
Appl. No.:
09/648816
Inventors:
Michael R. Yeaman - Torrance CA, US
Alexander J. Shen - Torrance CA, US
Alexander J. Shen - Torrance CA, US
Assignee:
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - Torrance CA
International Classification:
A61K 38/00, C07K 5/00
US Classification:
514 12, 514 13, 514 14, 530324, 530325, 530326, 530327, 530334, 530344
Abstract:
The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides, and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
Antimicrobial Peptides And Derived Metapeptides
US Patent:
8440792, May 14, 2013
Filed:
Oct 25, 2010
Appl. No.:
12/911693
Inventors:
Michael R. Yeaman - Redondo Beach CA, US
Alexander J. Shen - Torrance CA, US
Alexander J. Shen - Torrance CA, US
Assignee:
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - Torrance CA
International Classification:
C07K 7/00, C07K 7/08
US Classification:
530326, 530327, 514 214, 514 215
Abstract:
The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
Antimicrobial Peptides And Derived Metapeptides
US Patent:
2013024, Sep 19, 2013
Filed:
Feb 19, 2013
Appl. No.:
13/770924
Inventors:
Michael R. YEAMAN - Redondo Beach CA, US
Alexander J. Shen - Torrance CA, US
Alexander J. Shen - Torrance CA, US
Assignee:
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - Torrance CA
International Classification:
C07K 14/47
US Classification:
514 24, 514 33
Abstract:
The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.